Firms
Theme

BXP

BXP, Inc. · NYSE

News

4 latest

No direct coverage yet · Showing articles that mention BXP

Zacks Investment Research

What's in the Offing for Ventas Stock This Earnings Season?

Ventas (VTR) is set to report Q3 2026 results on October 27, with revenues projected to rise 18.3% and FFO per share up 11.4% year-over-year. Strong senior housing occupancy and long-term leases should support growth, but high interest expenses and declining triple-net rental income may weigh on results. The company has an Earnings ESP of +0.70% and Zacks Rank #3, suggesting a potential FFO beat.

Zacks Investment Research

Welltower Gears Up to Report Q3 Earnings: What's in the Cards?

Welltower, a healthcare REIT, is scheduled to report Q3 2026 results on October 26 with expected year-over-year revenue growth of 35% to $3.63 billion and normalized FFO per share growth of 22.4% to $1.64. Strong senior housing demand and muted new supply are expected to support performance, though high interest expenses may be a headwind. The company has a positive Earnings ESP of +0.30% and Zacks Rank #2 (Buy), suggesting potential for an FFO beat.

Zacks Investment Research

Here's Why Investors Should Retain Vornado Stock in Their Portfolio Now

Vornado Realty Trust's Manhattan office portfolio shows improving fundamentals with occupancy rising to 92.2% in June 2026 and strong leasing demand at $107.24 per sq. ft. The company is strategically investing in premium properties like 350 Park Avenue and Park Avenue Plaza while maintaining $2 billion in liquidity. However, heavy concentration in New York City, substantial debt obligations, and rising interest expenses pose significant challenges to earnings growth.

Zacks Investment Research

Prologis' Q3 FFO Beat Estimates as Rental Revenues Rise

Prologis (PLD) reported Q3 2026 core FFO of $1.60 per share, up 7.4% year-over-year and beating consensus estimates. Rental revenues grew 7.4% to $2.21B, while average occupancy improved to 95.1%. The company narrowed 2026 core FFO guidance to $6.25-$6.29 and raised development starts guidance to $5.0-$5.75B, reflecting strong operational performance and capital deployment plans.

Headlines link to the publisher. Not investment advice.

Analysts

All ›

Targets are shown as reported, adjusted only for stock splits, not as predictions. Not investment advice.

Community

7 days

No sentiment yet

Posts 24h
0
Replies 24h
0
Watchers
0

Board · $BXP · 0 threads

Sign in to post on $BXP

No threads yet

Community posts are member opinions. Desk posts are automated weekly counts. Not investment advice.

Cylvex is a financial simulation and community platform designed for educational and informational purposes only. Market data may be delayed. Nothing on this platform constitutes investment advice, financial advice, trading advice, or any other sort of advice. You should not treat any of the platform's content as such. Cylvex does not recommend that any financial instrument should be bought, sold, or held by you. Do conduct your own due diligence and consult your financial advisor before making any investment decisions. By using Cylvex, you acknowledge that you are using the platform at your own risk.

Terms · Privacy · Disclaimer · Methodology · Logos provided by Logo.dev